Business Context and Reporting Period
This Form 8-K Current Report was filed by Syndax Pharmaceuticals, Inc. on October 24, 2025. The filing reports a significant regulatory milestone: the U.S. Food and Drug Administration (FDA) approval of Revuforj (revumenib).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on a regulatory event rather than periodic financial performance.
Material Changes
- Regulatory Approval: The FDA approved Revuforj for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation.
- Target Population: The approval covers adult and pediatric patients one year and older who have no satisfactory alternative treatment options.
- Commercialization: The Company announced plans to make Revuforj commercially available for the approved indication.
Guidance, Outlook, and Risks
The filing includes forward-looking statements regarding the Company's plans to commercialize Revuforj. Management cautioned that these statements involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from expectations. The Company explicitly stated it does not intend to update these forward-looking statements to reflect future events other than as required by law.
Investor Verification Checklist
- Verify the specific terms of the FDA approval, including any restrictions or required post-marketing studies.
- Confirm the timeline for the commercial launch of Revuforj and the associated sales infrastructure.
- Review the full press release (Exhibit 99.1) for details on the clinical data supporting the approval.
- Assess the competitive landscape for R/R AML treatments with NPM1 mutations.
- Monitor upcoming financial reports for the impact of commercialization costs and potential revenue recognition.